Navigation Links
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
Date:9/15/2008

VANCOUVER, Sept. 15 /PRNewswire-FirstCall/ - MIGENIX Inc. (the "Company" or "MIGENIX") (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2008 and provides a corporate update on its programs and other matters.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): Cadence Pharmaceuticals, Inc. ("Cadence"), our development and commercialization partner, has today announced that it is engaged in discussions with the US Food and Drug Administration ("FDA") regarding the statistical analysis plan for the Central Line Infection Reduction Study ("CLIRS") Phase III trial and that these discussions, which are being conducted under a Special Protocol Assessment, must be completed prior to unblinding the data from the trial. As a result, Cadence revised its guidance for reporting the results of the CLIRS trial from the fourth quarter of calendar 2008 to the first quarter of calendar 2009. With positive results in the CLIRS trial, Cadence continues to expect to submit a New Drug Application ("NDA") for OmigardTM to the FDA in the second quarter of calendar 2009. Upon successful completion of various milestones in this program (starting with FDA acceptance of the NDA for filing), we can receive up to US$27MM in development and commercialization milestone payments and a double-digit royalty on net sales. Cadence's commercialization focus is on the United States market and thus Cadence intends to establish a strategic partnership(s) for the commercialization of Omigard(TM) for the rights it has outside of the United States. Our management and Board are working to out- license Omigard(TM) rights that lie outside of the Cadence agreement either in combination with Cadence's rights outside the US to prospective global partners or to potential regional partners for rest of w
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Migenix averts proxy contest; reaches agreement with DJohnson holdings
2. Notice of MIGENIX General Meeting of Shareholders
3. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX Corporate Update and Requisition of Special Meeting
5. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
6. MIGENIX Appoints Pieter Dorsman to Board of Directors
7. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
8. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. MIGENIX releases CEO message #22
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... N.J., Oct. 8 Managed Health Care,Associates, Inc. ... that it plans to open the 2008 MHA ... Secretary, Health and Human Services,(2001-2005), former four-term Governor ... Independent Chairman, Deloitte,Center for Health Solutions. Marking the ...
... announced today that it has entered into a ... producer of infant,formula products including the Similac(R) Advance(R) ... and ARA supplier for all of its,infant formula ... with,Abbott having the right to terminate the arrangement ...
... patients to benefit from rapid, long-lasting symptom control with ... ... fumarate -, NAPA, Calif., Oct. 8 Dey, L.P., ... the launch of Perforomist(TM),(formoterol fumarate) Inhalation Solution, which will be ...
Cached Biology Technology:MHA Announces: Tommy Thompson to be Keynote Speaker at The MHA 5th Annual Business Summit 2Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6
(Date:4/23/2014)... the first cause of dementia and affects some 400,000 ... yet been found. One of the reasons for this ... which cause alterations in nerve transmissions and the loss ... Researchers from the Institute of Neuroscience at the Universitat ... in memory consolidation and were able to develop a ...
(Date:4/23/2014)... April 23, 2014 A biomedical engineer at the ... innovative technology to make blood transfusions safer. His work ... National Institutes of Health (NIH). , Blood transfusions ... of modern medicine,s absolute necessities. Without them, for instance, ... transfusions are perfect, however. There,s strong evidence that transfusions ...
(Date:4/23/2014)... used to read quickly. It involves visual searching ... and/ or sentences. Similarly to humans, biological systems ... genetic information. Genes that need to be read ... encoding message, the easier it will be to ... de Cincia (IGC, Portugal) and Centre for Molecular ...
Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Cell division speed influences gene architecture 2
... CAMBRIDGE, Mass. The evolution of human speech was far ... link it to a specific gene, says Robert Berwick, professor ... ideas about language in a session at the annual meeting ... Sunday, Feb. 17. The session is called Mind of a ...
... considerations and fears about global warming have helped revive ... cleanly and can be produced from plants. But ... corn-based ethanol: the more corn is used in ethanol ... partly accounts for the recent run-up in world food ...
... and closely linked social and ecological systems along our ... Guerry says can be addressed by a new approach ... Guerry will discuss the use of ecosystem services, ... marine resources in her AAAS presentation Ecosystem Services Provided ...
Cached Biology News:MIT: No easy answers in evolution of human language 2MIT: No easy answers in evolution of human language 3MIT professor to discuss future of biofuels 2Can Dungeness crab and eelgrass help improve management of our marine resources? 2
AC input: 50-60 Hz230 V...
AC input: 50-60 Hz 115-120 V...
... reagent is formulated specifically for Alkaline Phosphatase ... levels of activity for both the enzyme ... final dilution. This product has been ... the customer a longer shelf life, resistance ...
... is a valuable tool for removing SDS ... of SDS in biological samples imparts a ... complex, inhibits enzymatic activity during digestion, and ... contaminant in mass spectrometry analyses. We ...
Biology Products: